

REMARKS


In response to the Restriction Requirement in the Office Action, Applicants elect, with traverse, the invention of Group 1, claims 1-5, 23-29, and 49, drawn to isolated nucleic acid molecules encoding the amino acid sequence of SEQ ID NO: 2.

Applicants respectfully request that once a product claim in Group I is found to be allowable, withdrawn process claims which depend from or otherwise include all the limitations of the allowable product claim, such as the claims of Groups 22, 29, 43, 64, 70, 77, and 84 (claims 35-37, 39, 43-48, 50-55), be rejoined (see MPEP 821.04).

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,
MORGAN, LEWIS & BOCKIUS LLP

Dated: December 9, 2003
MORGAN, LEWIS & BOCKIUS LLP
Customer No. 09629
1111 Pennsylvania Avenue, NW
Washington, DC 20004
Tel: 202-739-3000; Fax: 202-739-3001

By: 
Michael S. Tuscan, Ph.D.
Reg. No. 43,210